Abstract: The present invention relates to a method for modifying and cross-linking an anticoagulating hydrogel nanofilm for cell encapsulation. According to the present invention, the protection from the external environment and the control of material transfer can be improved due to the anticoagulant functionalization of the material surface. In addition, when applied into the body, it can prevent fibrosis, blood coagulation, protein adsorption, and platelet adhesion caused by immune responses, thereby preventing a decrease in cell viability caused by immune responses and improving cell survival rate.

Abstract: The present invention relates to miRNA-4449, which is a biomarker that can be used to diagnose nonalcoholic steatohepatitis, and at least one miRNA selected from the group consisting of miRNA-15, miRNA-21, miRNA-29, miRNA-126, miRNA-151, miRNA-183, and miRNA-192. The prognosis of nonalcoholic steatohepatitis among nonalcoholic fatty liver diseases is poor unlike simple steatosis. According to the present invention, the level of the miRNA can be measured in the serum of a patient to provide an accurate diagnostic result of nonalcoholic steatohepatitis, thus making it possible to eliminate side effects caused by conventional invasive test methods, and enabling early diagnosis and appropriate treatment of steatohepatitis in a simple and economical manner.

Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

Abstract: A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.

Abstract: A fluid reaction device includes a microfluidic reaction chip which accommodates a fluid, a heater, and a heat transfer facilitating layer which is interposed between the microfluidic reaction chip and the heater, the heat transfer facilitating layer has a higher thermal conductivity than air and can hold particles, wherein formation of an air layer can be prevented.

Abstract: Provided is a method for quantifying an initial concentration of a nucleic acid from a real-time nucleic acid amplification data. Nucleic acid (DNA or RNA) extracted from organism or virus is amplified using an enzyme. Then, the initial concentration of the nucleic acid is found by calculating the characteristic amplification cycle number or the characteristic amplification time at which the fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid has half of its maximum value, or the characteristic amplification cycle number or the characteristic amplification time at which the amplification efficiency has the maximum or the minimum value, or the prior-to-amplification fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid. Accordingly, the initial concentration of the nucleic acid can be calculated without differentiation or integration.

Abstract: Provided is a method for quantifying an initial concentration of a nucleic acid from a real-time nucleic acid amplification data. Nucleic acid (DNA or RNA) extracted from organism or virus is amplified using an enzyme. Then, the initial concentration of the nucleic acid is found by calculating the characteristic amplification cycle number or the characteristic amplification time at which the fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid has half of its maximum value, or the characteristic amplification cycle number or the characteristic amplification time at which the amplification efficiency has the maximum or the minimum value, or the prior-to-amplification fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid. Accordingly, the initial concentration of the nucleic acid can be calculated without differentiation or integration.

Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.

Abstract: Provided is a method of amplifying a nucleic acid using rolling cyclic amplification (RCA), including amplifying a nucleic acid together with formation of a single-strand circular DNA template using RCA by reacting a reaction solution including: (a) two hairpin oligos, (b) a target nucleic acid, (c) a DNA ligase, (d) an endonuclease, (e) a DNA polymerase, and (f) a primer.

Abstract: Disclosed is a method of determining an initial concentration of a target nucleic acid within a sample using real-time nucleic acid amplification data. Amplification efficiencies of the target nucleic acid with respect to amplification time are obtained from signals of amplified products, and an amplification efficiency function with respect to amplification time is formulated employing the amplification efficiencies.

Abstract: Provided is a method of amplifying a nucleic acid using rolling cyclic amplification (RCA), including amplifying a nucleic acid together with formation of a single-strand circular DNA template using RCA by reacting a reaction solution including: (a) two hairpin oligos, (b) a target nucleic acid, (c) a DNA ligase, (d) an endonuclease, (e) a DNA polymerase, and (f) a primer.

Abstract: Provided is kit for and a method of amplifying a nucleic acid using rolling cyclic amplification (RCA), including amplifying a nucleic acid together with formation of a single-strand circular DNA template using RCA by reacting a reaction solution including: (a) two hairpin oligos, (b) a target nucleic acid, (c) a DNA ligase,(d) an endonuclease, (e) a DNA polymerase, and (f) a primer.

Abstract: A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a biologically active molecule linked to the C-terminus of the membrane translocation sequence is disclosed herein. A polynucleotide encoding the transmembrane fusion protein, a recombinant expression vector including the polynucleotide sequence, a cell transformed by the recombinant expression vector, and a method of delivering the biologically active molecule into a cell using the transmembrane fusion protein are also disclosed.

Abstract: Provided are a centrifugal force based microfluidic device which can automatically perform a dilution operation and a microfluidic system including the same. The centrifugal force based microfluidic device for dilution includes a rotatable disk type platform, a mixing chamber disposed on the platform; a buffer solution storage disposed on a portion of the platform which is closer to a center of the platform than the mixing chamber, connected to the mixing chamber through a channel to supply a predetermined amount of buffer solution to the mixing chamber at least one time, and a plurality of diluted solution chambers which are disposed on a portion of the platform which is farther from the center of the platform than the mixing chamber, are each connected to the mixing chamber through flow paths extended from a middle exit corresponding to a predetermined water level, and sequentially receiving a solution which is serially diluted in the mixing chamber at least one time.

Abstract: A method of reducing a temperature difference between a high-temperature and a low-temperature substrate includes interposing a heat transfer facilitating layer which has a higher thermal conductivity than air and can hold particles between the substrates, and maintaining close contact between the high-temperature substrate, the heat transfer facilitating layer, and the low-temperature substrate, wherein formation of an air layer can be at least substantially prevented between the high-temperature substrate and the heat transfer facilitating layer, and between the low-temperature substrate and the heat transfer facilitating layer. A fluid reaction device includes a microfluidic reaction chip which accommodates a fluid, a heater, and a heat transfer facilitating layer which is interposed between the microfluidic reaction chip and the heater, the heat transfer facilitating layer has a higher thermal conductivity than air and can hold particles, wherein formation of an air layer can be prevented.

Abstract: A method of reducing a temperature difference between a high-temperature and a low-temperature substrate includes interposing a heat transfer facilitating layer which has a higher thermal conductivity than air and can hold particles between the substrates, and maintaining close contact between the high-temperature substrate, the heat transfer facilitating layer, and the low-temperature substrate, wherein formation of an air layer can be at least substantially prevented between the high-temperature substrate and the heat transfer facilitating layer, and between the low-temperature substrate and the heat transfer facilitating layer.

Abstract: A method of sequentially performing concentration and amplification of nucleic acid in a single micro chamber includes: introducing a nucleic acid-containing sample and a solution including a kosmotropic salt to a micro chamber having a hydrophilic interior surface to concentrate the nucleic acid by binding the nucleic acid on the interior surface of the micro chamber; and performing a polymerase chain reaction (PCR) by adding a PCR mixture to the chamber. Since the nucleic acid is reversibly bound to the interior surface of the micro chamber, PCR yield is higher compared with a surface of aluminum oxide in which irreversible binding occurs. In addition, all processes are sequentially performed in a single micro chamber so that the number of samples, consumables, time, and labor for treatment and analysis can be reduced, detection sensitivity can be improved, and risk of sample cross contamination significantly reduced without sample loss by eliminating transporting of the sample.

Abstract: A micro-fluid reaction vessel includes an upper plate formed of an elastomer, a lower plate adhered to the upper plate, a micro-chamber and a micro-channel formed on an inner surface of the upper plate facing the lower plate and an inlet hole and an outlet hole formed in the upper plate and through which a fluid flows into or out of, respectively. The micro-channel is constructed to be closed by pressure applied to the upper plate and elastically restored when the pressure is not applied. A micro fluid reaction method uses the micro fluid reaction vessel and a method of manufacturing forms the microfluid reaction vessel.

Abstract: Provided is a microfluidic device for electrochemically regulating the pH of a fluid. The microfluidic device includes: an ion-exchange material; an anode chamber having a surface defined by a surface of the ion-exchange material and an anode electrode disposed along an edge of the surface of the anode chamber; and a cathode chamber having a surface defined by a surface of the ion-exchange material and a cathode electrode disposed along an edge of the surface of the cathode chamber, wherein the anode chamber and the cathode chamber are separated by an insulation material.